

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Gilead Sciences, Inc.	Employment	Self
<i>Title:</i> Director, Clinical Research - Emerging and Respiratory Viruses <i>Additional Information:</i>		<i>Position Description:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Gilead Sciences	Other	Other - My host institution received financial recompense for local delivery of these trials.
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Local PI (and for this trial, UK CI) for remdesivir clinical trials

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Remdesivir for early treatment of COVID in ambulatory patients
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Centers for Disease Control and Prevention <i>Recipient Name:</i> Samuel Brown <i>Grant / Contract Description:</i> IVY Network studying COVID vaccine efficacy <i>Additional Information:</i>	Grant / Contract	Self <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Hamilton Health Sciences <i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>	Data And Safety Monitoring	Self <i>Description:</i> DSMB Chair for a mechanical ventilator trial
National Institutes of Health <i>Recipient Name:</i> Samuel Brown <i>Grant / Contract Description:</i> Investigator effort for COVID-19 trials. <i>Additional Information:</i>	Grant / Contract	Self <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
National Institutes of Health <i>Recipient Name:</i> Samuel Brown <i>Grant / Contract Description:</i> Service on CONNECTS steering committee for NHLBI. <i>Additional Information:</i>	Grant / Contract	Self <i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
Sedana <i>Category:</i> Consultant <i>Additional Information:</i> Support was paid to my employer, not to me.	Consultant	Self <i>Description:</i> Consulted on trial design for a sedation trial
U.S. Department of Defense <i>Recipient Name:</i> Samuel Brown <i>Grant / Contract Description:</i> Grant to study long-term outcomes after COVID associated respiratory failure. <i>Additional Information:</i>	Grant / Contract	Self <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Gilead Sciences Inc	Employment	Self
<i>Title:</i> Senior Research Scientist II <i>Additional Information:</i>		<i>Position Description:</i> Scientist in clinical virology
Gilead Sciences Inc	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Gilead Sciences, Inc.	Employment	Self
<i>Title:</i> Director Biostatistics <i>Additional Information:</i>		<i>Position Description:</i> Biostatistics lead of study
Gilead Sciences, Inc.	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Gilead Sciences Inc	Employment	Self
<i>Title:</i> Senior Vice President, Clinical Research		<i>Position Description:</i> Virology Therapeutic Area Clinical Development Leadership
<i>Additional Information:</i> Also a consultant to the Remdesivir Clinical Research Team from April, 2020 - July, 2021		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AbbVie	Grant / Contract	Self
<i>Recipient Name:</i> Adit Ginde <i>Grant / Contract Description:</i> Investigator initiated research grant for COVID-19 outpatient trial, outside the submitted work		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
Faron Pharmaceuticals	Grant / Contract	Self
<i>Recipient Name:</i> Adit Ginde <i>Grant / Contract Description:</i> Investigator initiated research grant for COVID-19 inpatient trial, outside the submitted work		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16846

Summary of Interests

Entity	Type	Interest Held By
Eli Lilly and Company	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Scientific Advisory Board
F. Hoffmann-La Roche	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Scientific Advisory Board
Gilead Sciences, Inc.	Gift	Other - Gift-in-kind to Baylor Scott & White Research Institute related to TROJAN-C trial (NCT03383419)
<i>Description:</i> Gift-in-Kind to Baylor Scott & White Research Institute related to TROJAN-C trial (NCT03383419) <i>Additional Information:</i>		
Gilead Sciences, Inc.	Grant / Contract	Other - Contract research fees to Baylor Scott & White Research Institute
<i>Recipient Name:</i> Baylor Scott and White Research Institute <i>Grant / Contract Description:</i> Contract research fees to Baylor Scott & White Research Institute <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Gilead Sciences, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Scientific Advisory Board
GlaxoSmithKline, LLC.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Scientific Advisory Board
Janssen Research & Development, LLC	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Kinevant Sciences	Consultant	Other - Consulting fees to Baylor Scott & White Research Institute
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Academic Steering Committee Member

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19

3. Are you the corresponding author?

Yes.

a. Please list the other authors' names here.

Carlos E. Vaca MD, Roger Paredes, MD, Jorge Mera, MD, Brandon J. Webb, MD, Gilberto Perez, MD, Godson Oguchi, MD, Pablo Ryan, MD, PhD, Bibi Uhre Nielsen, MD, Michael Brown, PhD, FRCP, Ausberto Hidalgo, Yessica Sachdeva, MD, Shilpi Mittal, MD, Olayemi Osiyemi, MD, Jacek Skarbinski, MD, Kavita Juneja, MD, Robert H. Hyland, DPhil, Anu Osinusi, MD, Shuguang Chen, PhD, Gregory Camus, PhD, Mazin Abdelghany, MD, Santosh Davies, MD, Nicole Behenna-Renton, Frank Duff, MD, 18 Francisco M. Marty, MD, Morgan Katz, MD, Adit A. Ginde, MD, MPH, Samuel M. Brown, MD, MS, Joshua T. Schiffer, MD, and Joshua A. Hill, MD, for the GS-US-540-9012 (PINETREE) Investigators

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Entity	Type	Interest Held By
allovir	Grant / Contract	Self
<i>Recipient Name:</i> Joshua A Hill <i>Grant / Contract Description:</i> clinical trial site PI and other research studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
allovir	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> expert on epidemiology of viral infections, assisting with clinical trial design
Deverra therapeutics	Grant / Contract	Self
<i>Recipient Name:</i> Joshua A Hill <i>Grant / Contract Description:</i> PI of investigator-initiated trial using their study product to treat patients with COVID-19 <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Gilead Sciences Inc	Grant / Contract	Self
<i>Recipient Name:</i> Joshua A Hill <i>Grant / Contract Description:</i> To conduct a clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Gilead Sciences Inc	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> 1 day		<i>Description:</i> Presented data on herpes viral infection epidemiology
Gilead Sciences Inc	Travel	Self
<i>Location(s):</i> foster city, california <i>Additional Information:</i>		<i>Purpose:</i> to present data on herpesvirus epidemiology to the company

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Gilead Sciences, Inc.	Employment	Self
<i>Title:</i> Senior Director, Clinical Development <i>Additional Information:</i>		<i>Position Description:</i>
Gilead Sciences, Inc.	Stock	Self
<i>Additional Information:</i>		
Gilead Sciences, Inc.	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
arly Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Gilead Sciences, Inc.	Employment	Self
<i>Title:</i> Senior Director, Virology Clinical Development		<i>Position Description:</i> Clinical development of therapeutics for viral disease (including remdesivir for SARS-CoV-2 infection)
<i>Additional Information:</i> Clinical lead and medical monitor for PINETREE study (GS-US-540-9012) evaluating efficacy and safety of 3-day IV RDV for treatment of high-risk individuals with COVID-19		
Gilead Sciences, Inc.	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Agency for Health Care Policy and Research	Grant / Contract	Self
<i>Recipient Name:</i> Johns Hopkins University School of Medicine <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Artis Senior Living	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> hourly rate		<i>Description:</i> Consulting on COVID- protocols and policies
Centers for Disease Control and Prevention	Grant / Contract	Self
<i>Recipient Name:</i> Johns Hopkins University School of Medicine <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Gilead Sciences Inc	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> I received a one time honorarium for participating in a panel for Gilead's COVID Patient-Centric Grand Rounds		<i>Description:</i> I received a one time honorarium

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
early outpatient remdesivir to prevent progression to severe Covid 19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16846

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16846

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to prevent progression to severe covid -19.
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Gilead Sciences	Employment	Self
<i>Title:</i> Vice president <i>Additional Information:</i>		<i>Position Description:</i> Clinical research
Gilead Sciences	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Entity	Type	Interest Held By
Gilead Sciences	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> advisory board
Gilead Sciences	Stock	Self
<i>Additional Information:</i>		
GlaxoSmithKline	Stock	Self
<i>Additional Information:</i>		
Merck	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> advisory board
Pfizer	Stock	Self
<i>Additional Information:</i>		
ViiV Healthcare	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> speaker program, advisory board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe COVID-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Eli Lilly and Company	Other	Self
Category: Other Additional Information:		Description: Scientific advisory board
Gilead Sciences	Grant / Contract	Self
Recipient Name: Grant / Contract Description: Additional Information:		Recipient Type: Grant / Contract Purpose:
Gilead Sciences	Other	Self
Category: Other Additional Information:		Description: Scientific advisory board
Merck	Grant / Contract	Self
Recipient Name: Grant / Contract Description: Additional Information:		Recipient Type: Grant / Contract Purpose:
Merck	Other	Self
Category: Other Additional Information:		Description: Scientific advisory board
Theratechnologies Inc.	Other	Self
Category: Other Additional Information:		Description: Scientific advisory board
ViiV Healthcare	Grant / Contract	Self
Recipient Name: Grant / Contract Description: Additional Information:		Recipient Type: Grant / Contract Purpose:
ViiV Healthcare	Other	Self
Category: Other Additional Information:		Description: Scientific advisory board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Gilead Sciences	Grant / Contract	Self
<i>Recipient Name:</i> Fundacion SEIMC-GESIDA <i>Grant / Contract Description:</i> IN-ES-380-6205 <i>Additional Information:</i> Simplified model of linkage & retention to care, using a mobile unit and a same-day test & treat approach among excluded population. The SIMPLIFIED Study.		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19" to the New England Journal of Medicine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16846

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Gilead Sciences Inc	Other	Self
<i>Category:</i> Other <i>Additional Information:</i> I helped assist Gilead in designing the clinical trial but was not compensated for this work/		<i>Description:</i> Advisor

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Genentech USA, Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Kaiser Foundation Research Institute <i>Grant / Contract Description:</i> Research contract to conduct COVID-19 related research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Gilead Sciences Inc	Grant / Contract	Self
<i>Recipient Name:</i> Kaiser Foundation Research Institute <i>Grant / Contract Description:</i> Funding for participants recruitment and follow-up for clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Karyopharm Therapeutics Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Kaiser Foundation Research Institute <i>Grant / Contract Description:</i> Funding to enroll patients in a clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16846

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. What is the manuscript title?**
Early outpatient Remdesivir to prevent progression of Covid19
- 3. Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16846

Summary of Interests

Entity	Type	Interest Held By
AbbVie Biotherapeutics	Other	Other - Institutional support; I received no direct remuneration for effort
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Site investigator for COVID therapeutic clinical trial
Agency for Healthcare Research and Quality	Grant / Contract	Self
<i>Recipient Name:</i> Brandon Webb <i>Grant / Contract Description:</i> R03 grant to study Clostridioides difficile <i>Additional Information:</i> Unrelated to COVID-19		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
Genentech	Other	Other - Institutional support; I received no direct remuneration for effort
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Site investigator for COVID therapeutic clinical trial
National Institutes of Health	Other	Other - Institutional support; I received no direct remuneration for effort
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Site Investigator for ACTIV COVID Trials
Regeneron Pharmaceuticals	Other	Other - Institutional support; I received no direct remuneration for effort
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Site investigator for COVID therapeutic trial

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Outpatient Remdesivir to Prevent Progression to Severe Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.